A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata

被引:159
|
作者
Trink, A. [1 ]
Sorbellini, E. [1 ]
Bezzola, P. [1 ]
Rodella, L. [2 ]
Rezzani, R. [2 ]
Ramot, Y. [3 ]
Rinaldi, F. [1 ]
机构
[1] IHRF, Milan, Italy
[2] Univ Brescia, Brescia, Italy
[3] Hadassah Hebrew Univ, Dept Dermatol, Med Ctr, Jerusalem, Israel
关键词
INVESTIGATIONAL ASSESSMENT GUIDELINES; POTENTIAL THERAPEUTIC TOOL; PROMOTING HAIR-GROWTH;
D O I
10.1111/bjd.12397
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Alopecia areata (AA) is a common autoimmune condition, causing inflammation-induced hair loss. This disease has very limited treatment possibilities, and no treatment is either curative or preventive. Platelet-rich plasma (PRP) has emerged as a new treatment modality in dermatology, and preliminary evidence has suggested that it might have a beneficial role in hair growth. Objectives To evaluate the efficacy and safety of PRP for the treatment of AA in a randomized, double-blind, placebo-and active-controlled, half-head, parallel-group study. Methods Forty-five patients with AA were randomized to receive intralesional injections of PRP, triamcinolone acetonide (TrA) or placebo on one half of their scalp. The other half was not treated. Three treatments were given for each patient, with intervals of 1 month. The endpoints were hair regrowth, hair dystrophy as measured by dermoscopy, burning or itching sensation, and cell proliferation as measured by Ki-67 evaluation. Patients were followed for 1 year. Results PRP was found to increase hair regrowth significantly and to decrease hair dystrophy and burning or itching sensation compared with TrA or placebo. Ki-67 levels, which served as markers for cell proliferation, were significantly higher with PRP. No side-effects were noted during treatment. Conclusions This pilot study, which is the first to investigate the effects of PRP on AA, suggests that PRP may serve as a safe and effective treatment option in AA, and calls for more extensive controlled studies with this method.
引用
收藏
页码:690 / 694
页数:5
相关论文
共 50 条
  • [21] Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study
    Malik, M.
    van Gelderen, E. M.
    Lee, J. H.
    Kowalski, D. L.
    Yen, M.
    Goldwater, R.
    Mujais, S. K.
    Schaddelee, M. P.
    de Koning, P.
    Kaibara, A.
    Moy, S. S.
    Keirns, J. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (06) : 696 - 706
  • [22] Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety
    Markman, John D.
    Bolash, Robert B.
    McAlindon, Timothy E.
    Kivitz, Alan J.
    Pombo-Suarez, Manuel
    Ohtori, Seiji
    Roemer, Frank W.
    Li, David J.
    Viktrup, Lars
    Bramson, Candace
    West, Christine R.
    Verburg, Kenneth M.
    PAIN, 2020, 161 (09) : 2068 - 2078
  • [23] Lumbar Intradiskal Platelet-Rich Plasma (PRP) Injections: A Prospective, Double-Blind, Randomized Controlled Study
    Tuakli-Wosornu, Yetsa A.
    Terry, Alon
    Boachie-Adjei, Kwadwo
    Harrison, Julian R.
    Gribbin, Caitlin K.
    LaSalle, Elizabeth E.
    Nguyen, Joseph T.
    Solomon, Jennifer L.
    Lutz, Gregory E.
    PM&R, 2016, 8 (01) : 1 - 10
  • [24] POSITIVE RESULTS WITH ITI-007 FOR THE TREATMENT OF SCHIZOPHRENIA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED PHASE 2 STUDY
    Vanover, Kimberly
    Davis, Robert E.
    Ereshefsky, Larry
    Mates, Sharon
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S278 - S279
  • [25] PLATELET-RICH PLASMA (PRP) IMPROVES ERECTILE FUNCTION: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL
    Poulios, E.
    Mykoniatis, I
    Pyrgidis, N.
    Zilotis, F.
    Kapoteli, V
    Kotsiris, D.
    Kalyvianakis, D.
    Hatzichristou, D.
    JOURNAL OF SEXUAL MEDICINE, 2022, 19 (05): : S157 - S158
  • [26] Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study
    Miller, Paul D.
    Chines, Arkadi A.
    Christiansen, Claus
    Hoeck, Hans C.
    Kendler, David L.
    Lewiecki, E. Michael
    Woodson, Grattan
    Levine, Amy B.
    Constantine, Ginger
    Delmas, Pierre D.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 (04) : 525 - 535
  • [27] Treatment of Lateral Epicondylitis With Platelet-Rich Plasma, Glucocorticoid, or Saline A Randomized, Double-Blind, Placebo-Controlled Trial
    Krogh, Thoger Persson
    Fredberg, Ulrich
    Stengaard-Pedersen, Kristian
    Christensen, Robin
    Jensen, Pia
    Ellingsen, Torkell
    AMERICAN JOURNAL OF SPORTS MEDICINE, 2013, 41 (03): : 625 - 635
  • [28] Platelet-Rich Plasma (PRP) Improves Erectile Function: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial
    Poulios, Evangelos
    Mykoniatis, Ioannis
    Pyrgidis, Nikolaos
    Zilotis, Filimon
    Kapoteli, Paraskevi
    Kotsiris, Dimitrios
    Kalyvianakis, Dimitrios
    Hatzichristou, Dimitrios
    JOURNAL OF SEXUAL MEDICINE, 2021, 18 (05): : 926 - 935
  • [29] Platelet-rich Plasma for the Treatment of Erectile Dysfunction: A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial
    Masterson, Thomas A.
    Molina, Manuel
    Ledesma, Braian
    Zucker, Isaac
    Saltzman, Russell
    Ibrahim, Emad
    Han, Sunwoo
    Reis, Isildinha M.
    Ramasamy, Ranjith
    JOURNAL OF UROLOGY, 2023, 210 (01): : 154 - 161
  • [30] A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of MIN-117 in Patients With Major Depressive Disorder
    Davidson, Michael
    Staner, Corinne
    Saoud, Jay
    Noel, Nadine
    Werner, Sandra
    Luthringer, Elisabeth
    Reilly, Joe
    Luthringer, Remy
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S370 - S370